Introduction
============

Concurrent chemoradiotherapy (CCRT) is the standard treatment for patients with locally advanced non-small cell lung cancer (NSCLC). CCRT is superior to radiation alone or to sequential chemoradiation in patients with unresectable stage IIIA or stage IIIB disease \[[@b1-crt-2018-125],[@b2-crt-2018-125]\]. However, the majority of patients treated with CCRT develop disease recurrence and 5-year survival is only 15%-20% \[[@b2-crt-2018-125]-[@b4-crt-2018-125]\].

Epidermal growth factor receptor (EGFR) mutations are detected in approximately 40% of NSCLC from Asian patients and 10%-20% of NSCLC from Caucasian patients \[[@b5-crt-2018-125],[@b6-crt-2018-125]\]. *EGFR* mutations are more frequently found in females, never smokers, and adenocarcinomas, regardless of ethnicity. Approximately 90% of *EGFR* tyrosine kinase inhibitor (TKI)‒sensitizing mutations are exon 19 deletions or exon 21 L858R point mutations \[[@b7-crt-2018-125]\]. Several *EGFR* TKIs, including gefitinib, erlotinib, and afatinib have been approved for treatment of advanced *EGFR*-mutant NSCLC as a first-line therapy. *EGFR* mutation is usually associated with overexpression of *EGFR*. It has been reported that *EGFR* overexpression is negatively correlated with radiation treatment \[[@b8-crt-2018-125]\].

Several clinical studies recently reported that in patients with locally advanced NSCLC with *EGFR* mutation, locoregional recurrence rate after radiotherapy (RT) is lower than in patients with wild-type *EGFR*, and *EGFR* mutation was associated with a better response to CCRT \[[@b9-crt-2018-125]\]. However, the patient population in the previous studies was heterogeneous in terms of stage and surgical resection rate across *EGFR* mutational status. In addition, the types of *EGFR* mutations were not confined to deletion in exon 19 or L858R \[[@b10-crt-2018-125]\].

This study was conducted to evaluate the relationship between *EGFR* mutation and clinical outcomes in patients with stage III non-squamous cell lung cancer treated with definitive CCRT.

Materials and Methods
=====================

1. Study design
---------------

From January 2008 to December 2013, 334 patients with pathologically confirmed stage III NSCLC were treated with definitive CCRT at Samsung Medical Center, Korea. NSCLC stage evaluation was based on the American Joint Committee on Cancer seventh edition cancer staging manual. A total of 134 patients diagnosed with squamous cell carcinoma were excluded from further analysis. Among 200 remaining patients, three patients who did not receive CCRT or received it at half the dose of planned radiation were also excluded ([Fig. 1](#f1-crt-2018-125){ref-type="fig"}).

The initial diagnosis of NSCLC was pathologically confirmed in all patients based on either bronchoscopy or percutaneous fine-needle biopsy. Diagnostic and staging workups included complete history and physical examination, chest computed tomography (CT), positron emission tomography‒computed tomography (PET/CT) scan. Histologic diagnosis was assessed according to the World Health Organization classification. For nodal stage evaluation, endobronchial ultrasound‒guided trans bronchial fine needle aspiration from a supraclavicular lymph node was performed for N2/N3 stage. *EGFR* (exon 18-21) mutation was detected using the peptide nucleic acid locked nucleic acid polymerase chain reaction clamp method as previously described \[[@b11-crt-2018-125]\].

The median RT dose was 66 Gy in 33 fractions using 4-10 MV photon beams generated by a linear accelerator (Varian Medical Systems Inc., Palo Alto, CA). Simulation CT scans were typically performed in the supine position at a thickness of 2.5-5 mm. The gross tumor volume (GTV) was defined as the volume of tumor identified based on all available clinical information, including radiologic imaging, PET scan, bronchoscopy, and mediastinoscopy.

The clinical target volume was generated by extending a 5-mm margin from the GTV, which was modified according to adjacent organs if necessary. Elective irradiation of the clinically uninvolved lymph node was not allowed. The most common concurrent chemotherapeutic regimen was docetaxel plus cisplatin. Chemotherapy consisted of six cycles of docetaxel 25 mg/m^2^ intravenously with cisplatin 25 mg/m^2^ intravenously weekly \[[@b12-crt-2018-125]\]. Other CCRT regimen included paclitaxel plus platinum based chemotherapy that consisted of six cycles of paclitaxel 50 mg/m^2^ intravenously with cisplatin 25 mg/m^2^ intravenously or carboplatin area under the curve 1.5 intravenously weekly. Paclitaxel or docetaxel was given for 1 hour after chlorpheniramine 4 mg intravenously, followed by and H2 blocker (ranitidine) intravenously, and dexamethasone 20 mg intravenously. The cisplatin or carboplatin was given for 30 minutes with standard antiemetic after docetaxel. The investigator decided on docetaxel plus cisplatin or paclitaxel plus platinum (cisplatin or carboplatin) regimens. Patients received additional consolidation chemotherapy following CCRT.

Medical records were reviewed to collect patient data including age, gender, *EGFR* mutation status, Eastern Cooperative Oncology Group (ECOG) performance status, and smoking history. Radiological response to CCRT was evaluated by CT scan following CCRT, and was classified as a complete response (CR), partial response (PR), stable disease (SD), or progressive disease according to Response Evaluation Criteria in Solid Tumors (RECIST) ver. 1.1 \[[@b13-crt-2018-125]\]. The early toxicities of treatment related pneumonitis and esophagitis were graded using Common Terminology Criteria for Adverse Events ver. 4.0. The first follow-up and response evaluation were scheduled 1 month after completion of CCRT with chest CT scan. Subsequent follow-up evaluations were conducted at 3-4-month intervals thereafter, and included alternating chest CT and whole-body PET/CT. The primary endpoints were progression-free survival (PFS) and overall survival (OS) according to the *EGFR* mutation status.

2. Statistical analysis
-----------------------

The chi-square test was used to compare the response rate and recurrence rate according to *EGFR* mutation. PFS was measured from the start date of CCRT to the date of documented treatment failure; death, disease progression, or date of censoring at last follow-up examination was considered treatment failure. OS was defined as the interval between the start date of CCRT and the date of death from any cause or the date of censoring. Rates of PFS and OS were calculated and compared using the Kaplan-Meier methods and the log-rank test. In addition, multivariate analysis was conducted using Cox regression models including *EGFR*, stage IIIB, and disease control rate (DCR) with a p-value less than 0.05 in the univariate analysis. And, in the multivariate analysis, only the *EGFR* mutation group and the wild type group were analyzed, and the *EGFR* unknown group was excluded from the mutivariable analysis. All statistical analyses were performed using the SPSS ver. 24 (IBM Corp., Armonk, NY) software package. Variables with a p-value of \< 0.05 were considered significant.

3. Ethical statement
--------------------

The Institutional Review Board of the Samsung Medical Center (2017-12-090) approved the study. The requirement of informed consent was waived as the study was based on the retrospective analyses of existing administrative and clinical data.

Results
=======

1. Patients characteristics
---------------------------

Among 334 patients, 197 patients met eligibility criteria excluding squamous cell lung cancer. The main clinical characteristics of patients are summarized in [Table 1](#t1-crt-2018-125){ref-type="table"}. A total of 117 specimens were adequate for *EGFR* mutation analysis and 81 patients had unknown *EGFR* status. A total of 81 patients had *EGFR* wild type and 36 patients had *EGFR* mutations (exon 19 deletion, n=18; L858R in exon 21, n=9; uncommon mutation \[G719X, L868, T790M\], n=9). The median age was 59 years (range, 28 to 80 years) and 136 patients (69.0%) were male. Regarding stage, 152 patients (77.2%) had stage IIIB NSCLC and 45 (22.8%) patients had stage IIIA NSCLC. A total of 131 patients (66.5%) were current/former smoker and 183 patients (92.9%) had ECOG performance status 0-1. Regarding chemotherapy, 128 patients (65.0%) received a docetaxel plus cisplatin regimen, 56 patients (28.4%) received a paclitaxel plus platinum regimen, eight patients (4.1%) received an etoposide plus cisplatin regimen, and five patients (2.5%) received other regimens.

2. Response to CCRT
-------------------

In the *EGFR* mutation group, one patient (2.8%) had CR, 25 patients (69.4%) had PR, six patients (16.7%) had SD, and four patients (11.1%) had progression following CCRT ([Table 2](#t2-crt-2018-125){ref-type="table"}). With *EGFR* wild type, 15 patients (18.1%) had CR, 61 patients (75.3%) had PR, three patients (3.7%) had SD, and two patients (2.5%) had progression following CCRT. There was a significant difference in overall response rate to CCRT between *EGFR* mutant and EGFR wild type group (72.2% vs. 93.8%, p \< 0.001).

3. PFS and OS
-------------

The median follow-up duration was 66.5 months (range, 1.9 to 114.5 months). One hundred sixty four patients (83.2%) experienced disease progression. Median PFS was 8.9 months for the *EGFR* mutation group versus 11.8 months for *EGFR* wild type versus 10.5 months for *EGFR* unknown group ([Fig. 2](#f2-crt-2018-125){ref-type="fig"}). The *EGFR* mutation group had a short PFS compared with the *EGFR* wild type group (p=0.013) or *EGFR* unknown group (p=0.042). By univariate analysis including *EGFR* mutation, DCR and stage was an independent factor for shorter PFS. By multivariate analysis, *EGFR* mutation group had a shorter PFS than the *EGFR* wild type group, although the *EGFR* mutation was not statistically significant (hazard ratio, 1.492; 95% confidence interval, 0.968 to 2.229; p=0.070) ([Table 3](#t3-crt-2018-125){ref-type="table"}). Among the *EGFR* mutant group, median PFS was 8.5 months for the exon 19 deletion group vs. 9.4 months for the L858R group vs. 9.4 months for the unknown group (p=0.900) ([Fig. 3](#f3-crt-2018-125){ref-type="fig"}).

A total of 132 patients (67.0%) died during the follow-up period. The median OS was 34.6 months for the *EGFR* mutant group versus 31.9 months for the *EGFR* wild type group versus 22.6 months for the *EGFR* unknown group (p=0.214) ([Fig. 2](#f2-crt-2018-125){ref-type="fig"}). There was no significant difference in median OS according to *EGFR* mutation type. Twenty-nine patients (80.6%) with *EGFR* mutation were treated with EGFR TKIs (gefitinib, n=24; erlotinib, n=3; afatinib, n=2) on progression. The median OS was 49.8 months for exon 19 deletions, 28.1 months for L858R and 25.1 months for uncommon EGFR mutation (p=0.087) ([Fig. 3](#f3-crt-2018-125){ref-type="fig"}).

4. Recurrence
-------------

One hundred forty-nine patients (75.6%) experienced tumor recurrence without death. The most common failure pattern was systemic recurrence which was observed in 99 patients (66.4%). This was followed by loco-regional recurrence plus systemic recurrence in 32 patients (21.5%) and loco-regional recurrence in 18 patients (12.1%) ([Table 4](#t4-crt-2018-125){ref-type="table"}). Among 36 patients with *EGFR* mutation, 33 patients (91.7%) developed tumor recurrence without death, 23 patients (69.7%) had systemic recurrence, seven patients (21.2%) had loco-regional recurrence plus systemic recurrence, and three patients (9.1%) had loco-regional recurrence. The most common site of distant metastasis in the *EGFR* mutant group was the brain in nine patients followed by pleural metastasis in six patients, bone metastasis in five patients, lung to lung metastasis in five patients, distant lymph node metastasis in three patients, adrenal gland metastasis in two patients and liver metastasis in one patient. In the *EGFR* wild type group, pleural metastasis (15 patients, 18.5%) was the most common metastatic lesion, followed by brain (13 patients, 16.0%). In the *EGFR* unknown group, the brain was the most common metastatic site (16 patients, 20.0%). The median distant metastasis free survival (DMFS) was 9.3 months for the *EGFR* mutant group versus 13.2 months for *EGFR* wild type versus 13.6 months for the *EGFR* unknown group. The *EGFR* mutation group had a short DMFS compared with the *EGFR* wild type group (p=0.022) and *EGFR* unknown group (p=0.013). The median loco-regional recurrence free survival was 23.2 months for the *EGFR* mutant group versus 50.9 months for the *EGFR* wild type group (p=0.184) ([Fig. 4](#f4-crt-2018-125){ref-type="fig"}).

Discussion
==========

In this study, PFS was significantly shorter in patients with *EGFR* mutations compared to the *EGFR* wild type or unknown *EGFR* groups. The most common recurrence pattern was systemic with or without loco-regional recurrence, which was observed in more than 87.9% of patients. It was previously reported that *EGFR* mutation was associated with more frequent distant relapse and worse 5-year PFS rate after neoadjuvant CCRT followed by surgery in locally advanced mediastinoscopic N2-positive NSCLC \[[@b14-crt-2018-125]\]. These findings suggest that systemic control is more important in patients with locally advanced adenocarcinoma with *EGFR* mutations. Given the high incidence of systemic recurrence and limited clinical outcomes in *EGFR* mutant patients, a randomized phase III trial of maintenance gefitinib after CCRT in locally advanced NSCLC (SWOG S0023) was conducted to evaluate whether maintenance gefitinib improved clinical outcomes \[[@b15-crt-2018-125]\]. Unexpectedly, patients who received gefitinib as maintenance had worse survival compared to gefitinib and experienced more adverse events, although only few patients have *EGFR* mutation \[[@b16-crt-2018-125]\]. In our study, the PFS was significantly shorter in patients with *EGFR* mutation compared with *EGFR* wild type. The OS in our study did not show any significant difference between the two groups due to salvage therapy with EGFR TKI after progression. Another concern is the development of resistance to maintenance EGFR TKI. Therefore, it remains unclear whether maintenance EGFR TKI improves OS in stage III NSCLC patients after completion of CCRT.

Intriguingly, we also found that the brain was the most frequent site of distant metastasis in patients with *EGFR* mutation, consistent with other studies \[[@b17-crt-2018-125],[@b18-crt-2018-125]\]. This finding suggests that prophylactic central nervous system irradiation (PCI) might benefit patients with *EGFR* mutation. Recently, PCI in locally advanced NSCLC after CCRT did not show any survival benefit although the relapse rate in brain decreased \[[@b19-crt-2018-125]\]. Thus, the role of PCI in stage III *EGFR* mutant NSCLC must be investigated further. In contrast, the thirdgeneration EGFR TKI osimertinib is a candidate for consolidation therapy because of its high permeability to the brain and promising central nervous system efficacy \[[@b20-crt-2018-125],[@b21-crt-2018-125]\]. In contrast, the locoregional recurrence rate of the *EGFR* mutation group (9.1%) was not significantly different from that of the *EGFR* wild type group (10.9%), which is not consistent with previous studies \[[@b17-crt-2018-125]\] and needs further evaluation. Of note, the response rate to CCRT in the *EGFR* mutation group was also significantly lower than those of the *EGFR* wild type group. However, there was no significant difference in OS between the *EGFR* mutation group and the *EGFR* wild type group. Although no significant difference in PFS was observed according to *EGFR* mutation type, the median OS was longest in patients with exon 19 deletions.

Recently, a randomized phase III study of maintenance durvalumab, anti--PD-L1 immune check point inhibitor after completion of CCRT in stage III NSCLC patients (PACIFIC), demonstrated significant improvement of PFS compared to placebo (16.8 months vs. 5.6 months) \[[@b22-crt-2018-125]\]. In this study, only 6.1% of patients had *EGFR* mutations. Given that immune checkpoint inhibitors do not improve OS in *EGFR* mutant NSCLC by meta-analysis, there is a high possibility that durvalumab as consolidation therapy may not be beneficial to patients with *EGFR* mutant stage III NSCLC after completion of CCRT. Subgroup analysis in patients with *EGFR* mutation showed a hazard ratio of 0.76 (95% confidence interval, 0.35 to 1.64), suggesting patients with *EGFR* mutation might not benefit from maintenance durvalumab in this setting \[[@b23-crt-2018-125]-[@b25-crt-2018-125]\]. Although retrospective nature of analysis and single center study, it is one of the largest series of cohort patient dataset treated with CCRT along with long-term follow-up comparing *EGFR* mutation and wild type.

In conclusion, *EGFR* mutation was associated with short PFS and brain was the most common site of distant metastasis in patients with stage III non-squamous cell lung cancer treated with CCRT. To improve clinical outcome in this specific subset of patients, further study with novel agent should be investigated.
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###### 

Baseline characteristics according to *EGFR* mutation

  Characteristic                  Total (n=197)         EGFR mutation (n=36)   EGFR wild (n=81)      Unknown (n=80)
  ------------------------------- --------------------- ---------------------- --------------------- ---------------------
  **Age (yr)**                    59.0 (28-80)          52.0 (39-70)           60.0 (28-78)          63.0 (31-80)
   ≥ 60                           98 (49.7)             9 (25.0)               41 (50.6)             48 (60.0)
  **Sex**                                                                                            
   Male                           136 (69.0)            13 (36.1)              59 (72.8)             64 (80.0)
   Female                         61 (31.0)             23 (63.9)              22 (27.0)             16 (20.0)
  **Smoking status**                                                                                 
   Never smoker                   66 (33.5)             24 (66.7)              24 (29.6)             18 (22.5)
   Current/Former smoker          131 (66.5)            12 (33.3)              57 (70.4)             62 (77.5)
  **ECOG performance status**                                                                        
   0-1                            183 (92.9)            35 (97.2)              77 (92.8)             73 (91.2)
   2                              14 (7.1)              1 (2.8)                6 (7.2)               7 (8.8)
  **Clinical T classification**                                                                      
   cT1-2                          116 (58.9)            22 (61.1)              46 (56.8)             48 (60.0)
   cT3-4                          81 (41.1)             14 (38.9)              35 (43.2)             32 (40.0)
  **Clinical node involvement**                                                                      
   N1-2                           62 (31.5)             8 (22.2)               24 (29.6)             30 (37.5)
   N3                             135 (68.5)            28 (77.8)              57 (70.4)             50 (62.5)
  **Stage**                                                                                          
   IIIA                           45 (22.8)             5 (13.9)               15 (18.5)             25 (31.3)
   IIIB                           152 (77.2)            31 (86.1)              66 (81.5)             55 (68.7)
  **Pathology**                                                                                      
   Adenocarcinoma                 189 (95.9)            36 (100)               78 (96.3)             75 (93.8)
   Large cell carcinoma           5 (2.5)               \-                     1 (1.2)               4 (5.0)
   Adenosquamous carcinoma        3 (1.5)               \-                     2 (2.5)               1 (1.3)
  ***EGFR* mutation**                                                                                
   Deletion in exon 19            \-                    18 (50.0)              \-                    \-
   L858R                          \-                    9 (25.0)               \-                    \-
   Uncommon                       \-                    9 (25.0)               \-                    \-
  **Regimen of CCRT**                                                                                
   Docetaxel+cisplatin            128 (65.0)            22 (61.1)              47 (58.0)             59 (73.8)
   Paclitaxel+platinum            56 (28.4)             10 (27.8)              28 (34.6)             18 (22.5)
   Etoposide+cisplatin            8 (4.1)               1 (2.8)                4 (4.9)               3 (3.7)
   Others                         5 (2.5)               3 (8.3)                2 (2.5)               0
  **Complete radiation**          190 (96.4)            36 (100)               79 (97.5)             75 (93.8)
   Radiation (Gy)                 6,600 (1,800-7,400)   6,600 (6,200-7,400)    6,600 (4,400-7,400)   6,600 (1,800-7,400)
  **Follow-up duration (mo)**     66.5                  66.8                   66.5                  64.3

Values are presented as median (range) or number (%). EGFR, epidermal growth factor receptor; ECOG, Eastern Cooperative Oncology Group; CCRT, concurrent chemoradiotherapy.

###### 

Response according to EGFR mutation during concurrent chemoradiotherapy

  Efficacy of CCRT    Total (n=197)   EGFR mutation (n=36)   EGFR wild (n=81)   Unknown (n=80)   p-value
  ------------------- --------------- ---------------------- ------------------ ---------------- ----------
  **CCRT response**                                                                              
   CR                 33 (16.8)       1 (2.8)                15 (18.5)          17 (21.2)        \< 0.001
   PR                 126 (64.0)      25 (69.4)              61 (75.3)          40 (50.0)        
   SD                 24 (12.2)       6 (16.7)               3 (3.7)            15 (18.8)        
   PD                 14 (7.0)        4 (11.1)               2 (2.5)            8 (10.0)         
  **ORR**             159 (80.7)      26 (72.2)              76 (93.8)          57 (71.3)        \< 0.001
  **DCR**             183 (92.9)      32 (88.9)              79 (97.5)          72 (90.0)        0.104

Values are presented as number (%). EGFR, epidermal growth factor receptor; CCRT, chemoradiotherapy; CR, complete response; PR, partial response; SD, stable disease; PD, progressive disease; ORR, objective response rate; DCR, disease control rate.

###### 

Univariate and multivariable analyses of progression-free survival

  Variable                                                         Univariate analysis   Multivariable analysis                                 
  ---------------------------------------------------------------- --------------------- ------------------------ ------- ------- ------------- -------
  Age \> 60 yr                                                     0.946                 0.639                    0.783   \-      \-            \-
  Female                                                           1.456                 0.979-2.166              0.063   \-      \-            \-
  ECOG ≥ 2                                                         1.254                 0.578-2.721              0.566   \-      \-            \-
  Smoker                                                           0.691                 0.466-1.025              0.066   \-      \-            \-
  *EGFR* mutation^[a)](#tfn1-crt-2018-125){ref-type="table-fn"}^   1.681                 1.108-2.511              0.015   1.492   0.968-2.229   0.070
  Stage IIIB                                                       1.911                 1.098-3.326              0.022   1.780   1.018-3.110   0.043
  DCR                                                              0.412                 0.179-0.944              0.036   0.542   0.230-1.282   0.163

HR, hazard ratio; CI, confidence interval; ECOG, Eastern Cooperative Oncology Group; EGFR, epidermal growth factor receptor, DCR, disease control rate.

*EGFR* mutation type compared with *EGFR* wild type.

###### 

Recurrence rate and recurrence pattern

  Variable                                  Total (n=198)   *EGFR* mutation (n=36)   *EGFR* wild (n=81)   Unknown (n=80)   p-value
  ----------------------------------------- --------------- ------------------------ -------------------- ---------------- ---------
  **Recurrence rate**                       149 (75.6)      33 (91.7)                64 (79.0)            52 (65.0)        0.005
   Loco-regional recurrence                 18 (12.1)       3 (9.1)                  7 (10.9)             8 (15.4)         0.793
   Loco-regional plus systemic recurrence   32 (21.5)       7 (21.2)                 16 (25.0)            9 (17.3)         
   Systemic recurrence                      99 (66.4)       23 (69.7)                41 (64.1)            35 (67.3)        

Values are presented as number (%). EGFR, epidermal growth factor receptor.
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